Evidence map›Paper›PMID 21030483›Full record

ArticleLearning & memory (Cold Spring Harbor, N.Y.)2010

Central cannabinoid receptors modulate acquisition of eyeblink conditioning.

Adam B Steinmetz, John H Freeman

Open access · diamondAbstract read
In one paragraph

Article in Learning & memory (Cold Spring Harbor, N.Y.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015
    Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Adam B SteinmetzDepartment of Psychology, University of Iowa, Iowa City, Iowa 52242, USA.
John H Freeman
University of Iowa · US

Funding

Neural Pathways for Conditioned Stimuli in Eyeblink ConditioningR01MH080005 · NIMH · UNIVERSITY OF IOWA · PI FREEMAN, JOHN H · 2007 to 2014
$2.4M
NIMH NIH HHS MH080005NIMH NIH HHS R01 MH080005
6 · The paper itself

Abstract

Delay eyeblink conditioning is established by paired presentations of a conditioned stimulus (CS) such as a tone or light, and an unconditioned stimulus (US) that elicits the blink reflex. Conditioned stimulus information is projected from the basilar pontine nuclei to the cerebellar interpositus nucleus and cortex. The cerebellar cortex, particularly the molecular layer, contains a high density of cannabinoid receptors (CB1R). The CB1Rs are located on the axon terminals of parallel fibers, stellate cells, and basket cells where they inhibit neurotransmitter release. The present study examined the effects of a CB1R agonist WIN55,212-2 and antagonist SR141716A on the acquisition of delay eyeblink conditioning in rats. Rats were given subcutaneous administration of 1, 2, or 3 mg/kg of WIN55,212-2 or 1, 3, or 5 mg/kg of SR141716A before each day of acquisition training (10 sessions). Dose-dependent impairments in acquisition were found for WIN55,212-2 and SR141716A, with no effects on spontaneous or nonassociative blinking. However, the magnitude of impairment was greater for WIN55,212-2 than SR141716A. Dose-dependent impairments in conditioned blink response (CR) amplitude and timing were found with WIN55,212-2 but not with SR141716A. The findings support the hypothesis that CB1Rs in the cerebellar cortex play an important role in plasticity mechanisms underlying eyeblink conditioning.

Indexed as

AnimalsBenzoxazinesBlinkingCalcium Channel BlockersCerebellumConditioning, EyelidMaleMorpholinesNaphthalenesNeuronal PlasticityPiperidinesPyrazolesRatsRats, Long-EvansReceptor, Cannabinoid, CB1Rimonabant(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanoneBenzoxazinesCalcium Channel BlockersMorpholinesNaphthalenesPiperidinesPyrazolesReceptor, Cannabinoid, CB1Rimonabant

Identifiers

PMID21030483
PMCPMC2981415
OpenAlexW1989715658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.